Should I buy or sell XOMA stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA shares. View XOMA analyst ratings or view top-rated stocks .

What is XOMA's stock price target for 2024?

1 Wall Street analysts have issued 1 year price targets for XOMA's shares. Their XOMA share price targets range from $74.00 to $74.00. On average, they anticipate the company's stock price to reach $74.00 in the next year. This suggests a possible upside of 200.9% from the stock's current price. View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts .

How have XOMA shares performed in 2024?

XOMA's stock was trading at $18.50 at the beginning of the year. Since then, XOMA shares have increased by 32.9% and is now trading at $24.59. View the best growth stocks for 2024 here .

When is XOMA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XOMA earnings forecast .

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Friday, March, 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.13. The biotechnology company had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative net margin of 886.91% and a negative trailing twelve-month return on equity of 25.17%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com . John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK) , Alnylam Pharmaceuticals (ALNY) , Ascent Solar Technologies (ASTI) , CTI BioPharma (CTIC) , OPKO Health (OPK) , Uranium Energy (UEC) , Gilead Sciences (GILD) , NXP Semiconductors (NXPI) and Ekso Bionics (EKSO) .

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XOMA

XOMA (XOMA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free xoma Stock Alerts

$24.59

+0.34 (+1.40%)

(As of 04/18/2024 ET)

Compare

Today's Range: $24.24
▼
$24.90
50-Day Range: $19.52
▼
$26.35
52-Week Range: $13.48
▼
$27.00

Volume: 14,874 shs
Average Volume: 21,560 shs
Market Capitalization: $286.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.00

Get XOMA alerts:

XOMA MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 200.9% Upside
$74.00 Price Target
Short Interest: Bearish
2.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.22
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.73) to ($1.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

273rd out of 918 stocks

Pharmaceutical Preparations Industry

109th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
XOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
XOMA has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.36% of the outstanding shares of XOMA have been sold short.
Short Interest Ratio / Days to Cover
XOMA has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
Change versus previous month
Short interest in XOMA has recently decreased by 0.15%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
XOMA does not currently pay a dividend.
Dividend Growth
XOMA does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
XOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for XOMA is -0.22.

2.0

News and Social Media Coverage

News Sentiment
XOMA has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for XOMA this week, compared to 1 article on an average week.
Search Interest
2 people have searched for XOMA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, XOMA insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.20% of the stock of XOMA is held by insiders.
Percentage Held by Institutions
95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for XOMA are expected to grow in the coming year, from ($1.73) to ($1.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of XOMA is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of XOMA is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
XOMA has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About XOMA Stock (NASDAQ:XOMA)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XOMA Stock News Headlines

April 17, 2024 | americanbankingnews.com

XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93

April 3, 2024 | globenewswire.com

XOMA Corporation Announces Closing of Tender Offer

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | globenewswire.com

XOMA Declares Quarterly Preferred Stock Dividends

March 19, 2024 | globenewswire.com

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

March 13, 2024 | businesswire.com

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

March 8, 2024 | investorplace.com

XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023

March 8, 2024 | finance.yahoo.com

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 8, 2024 | globenewswire.com

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

February 28, 2024 | globenewswire.com

XOMA to Present at Upcoming Investor Conferences in March

February 19, 2024 | businesswire.com

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

February 18, 2024 | msn.com

Compare with Maple Leaf Green World Inc (4HV0)

February 17, 2024 | finance.yahoo.com

XOMA Mar 2024 20.000 put

February 17, 2024 | finance.yahoo.com

XOMA Jun 2024 25.000 call

February 16, 2024 | benzinga.com

Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma

February 16, 2024 | marketwatch.com

XOMA Agrees to Acquire Kinnate Biopharma

February 16, 2024 | finance.yahoo.com

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 16, 2024 | finance.yahoo.com

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 16, 2024 | globenewswire.com

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

January 20, 2024 | finance.yahoo.com

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

January 11, 2024 | markets.businessinsider.com

XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC

January 11, 2024 | tmcnet.com

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

January 11, 2024 | marketwatch.com

Xoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol

January 11, 2024 | markets.businessinsider.com

Xoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomol

January 11, 2024 | finance.yahoo.com

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

January 8, 2024 | seekingalpha.com

Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman

See More Headlines

Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:XOMA
CUSIP: 98419J10
CIK: 791908
Web: www.xoma.com
Phone: (510) 204-7200
Fax: 510-649-7571
Employees: 13
Year Founded: 1981

Price Target and Rating

Average Stock Price Target: $74.00
High Stock Price Target: $74.00
Low Stock Price Target: $74.00
Potential Upside/Downside: +200.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,830,000.00
Net Margins: -886.91%
Pretax Margin: -858.16%
Return on Equity: -25.17%
Return on Assets: -17.08%

Debt

Debt-to-Equity Ratio: 1.34
Current Ratio: 8.68
Quick Ratio: 8.68

Sales & Book Value

Annual Sales: $4.76 million
Price / Sales: 60.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.72 per share
Price / Book: 3.19

Miscellaneous

Outstanding Shares: 11,635,000
Free Float: 10,797,000
Market Cap: $286.10 million
Optionable: Optionable
Beta: 0.58

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Owen P. Hughes Jr. (Age 49)
CEO & Director
Comp: $193.75k
Mr. Thomas M. Burns (Age 50)
Senior VP of Finance & CFO
Comp: $759.24k
Mr. Brad Sitko (Age 43)
Chief Investment Officer
Comp: $867.08k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XOMA Stock Analysis - Frequently Asked Questions

Should I buy or sell XOMA stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings or view top-rated stocks.
What is XOMA's stock price target for 2024?: 1 Wall Street analysts have issued 1 year price targets for XOMA's shares. Their XOMA share price targets range from $74.00 to $74.00. On average, they anticipate the company's stock price to reach $74.00 in the next year. This suggests a possible upside of 200.9% from the stock's current price.
View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts.
How have XOMA shares performed in 2024?: XOMA's stock was trading at $18.50 at the beginning of the year. Since then, XOMA shares have increased by 32.9% and is now trading at $24.59.
View the best growth stocks for 2024 here.
When is XOMA's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XOMA earnings forecast.

How were XOMA's earnings last quarter?: XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Friday, March, 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.13. The biotechnology company had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative net margin of 886.91% and a negative trailing twelve-month return on equity of 25.17%.
What is John Varian's approval rating as XOMA's CEO?: 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.
What other stocks do shareholders of XOMA own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).
How do I buy shares of XOMA?: Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XOMA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

XOMA (XOMA) Stock Price, News & Analysis

XOMA MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About XOMA Stock (NASDAQ:XOMA)

XOMA Stock Price History

XOMA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

XOMA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™